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Background: Dynemicin A is an exceedingly potent 
antitumor antibiotic derived from microbial fermentation 
that cleaves double-stranded B-form DNA in vitro in the 
presence of activating factors such as NADPH or glu- 
tathione. Because of the structural complexity, high reac- 
tivity, and scarcity of natural dynemicin A, it has not been 
feasible to modify the structure to any significant extent. 
Previous studies have not determined the absolute 
configuration of the natural product. 
Results: A multistep route for the preparation of enan- 
tiomerically pure, synthetic dynemicin A was developed. 
The absolute configuration of natural dynernicin was 
determined by comparing the synthetic drug with dyne- 
micin A derived from fermentation. The route that was 
developed is highly convergent, as the result of a late-stage 
coupling reaction that combines two complex synthetic 
fragments, and has been shown to provide access to non- 
natural dynemicins of wide structural variability by modi- 
fications of these fragments. In this way, several nonnatural 
dynemicins, unavailable by any other means, were synthe- 
sized and shown to have DNA-cleaving activity in the 
presence of glutathione or NADPH. 
Conclusions: Enantiomerically pure dynernicin A is 
now available by laboratory synthesis. The natural, (+)- 
enantiomer of dynemicin A is shown to possess the 2S, 
3S, 4S, 7R, 8R configuration. A wide variety of hereto- 
fore unavailable, active analogs of dynemicin A have been 
prepared and are found to produce subtle variations in 
sequence specificity of DNA cleavage compared to the 
natural product and, of potentially greater significance, 
display variations in the efficiency of DNA cleavage as a 
function of the activating agent. 
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Introduction 
Fermentation of the microorganism Micromonosporu 
chersina produces a broth with potent antitumor and 
antibiotic properties.This bioactivity has been traced to a 
deep violet metabolite known as dynemicin A (Fig. 1). 
The relative, but not absolute, stereochemistry of this 
molecule was established by X-ray crystallographic 
H-O 
Dynemicin A (1) 
Fig. 1. The structure of dynemicin A (compound 1). 
analysis [l]. Dynemicin A (compound 1) exhibits 
remarkable antitumor activity, with LD,, values in the 
picogram to nanogram per ml range against many tumor 
cell lines. This, in conjunction with its reportedly low 
acute toxicity, defines 1 as an important new chemother- 
apeutic lead [2]. Dynemicin A (1) is unique among 
natural antitumor agents, possessing features of both the 
anthracycline and enecliyne antibiotic families. The 
highly reactive anthraquinone fragment imbues the 
molecule with its deep violet color and is characteristic 
of the anthracyclines, while the (.Z)-enediyne bridge and 
epoxide ring classify it among the enediyne antibiotics 
[3]. In parallel with other members of the enediyne 
antibiotic family, dynemicin A has been proposed to 
function in viva as a DNA-damaging agent. It has been 
amply demonstrated that compound 1 is capable of 
cleaving double-stranded B-form DNA in vitro in the 
presence of a reducing cofactor such as NADPH or 
a thiol, and Sugiura and co-workers [4--61 have provided 
convincing evidence that 1 is transformed into the 
biraclical intermediate shown in Fig. 2 upon reductive 
activation. This proposal requires initial reaction at the 
anthraquinone site, followed sequentially by epoxide 
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Fig. 2. Proposed mechanism of action 
of dynemicin A [4-61. Reduction at the 
anthraquinone site is followed by open- 
ing of the epoxide ring, tautomerization 
and Bergman cyclization of the strained 
CL’)-enediyne group to produce a highly 
reactive biradical intermediate. 
opening, tautomerization, and Bergman cyclization of 
the strained (Z)-enediyne group. The detailed interplay 
between complex functional groups can be seen to 
establish the unique reactivity profile of 1 and defines an 
exceptionally challenging problem in chemical synthesis. 
As a result of this reactivity profile, only limited chemical 
modifications of the natural product have been feasible. 
Consideration of the mechanism shown in Fig. 2 leads 
naturally to proposed studies involving more extensive 
modifications of the dynemicin structure, for example, 
nuclear substitution of the anthraquinone ring. Implicit 
in the design of dynemicin analogs of this type is a 
virtual requirement for the development of a laboratory 
synthetic route. Several research groups have reported 
notable advances toward the development of laboratory 
routes to dynemicin analogs of various kinds, both 
simple and complex [7-171. With regard to synthetic 
design, perhaps less apparent, but no less important, is the 
need for a convergent approach, in which structural vari- 
ability is introduced late in the synthetic route so as to 
achieve maximum structural divergence. The develop- 
ment of such a route has been the objective of our 
research for some time; its realization and application to 
the first preparation of enantiomerically pure dynemicin 
A and a wide variety of structural analogs is the subject 
of this report. 
Results and discussion 
Chemical synthesis 
Both natural and nonnatural dynemicins were 
envisioned to arise from the retrosynthetic fragments 
illustrated in Fig. 3 for a generalized dynemicin target 
molecule. In this strategy, the anthraquinone moiety is 
introduced at a very late stage in the synthetic scheme, a 
t 
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Fig. 3. Generalized retrosynthetic analysis 
of the dynemicins and structural analogs. 
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otherwise handled as bona jde synthetic intermediates, 
&&jr;; & &:: 
and have been transformed into anthraquinones by two 
different methods. The first employs a Diels-Alder 
cycloaddition/oxidation reaction sequence and is illus- 
trated with the preparation of the dideoxydynemicin 
analog 10 (Fig. 5). Heating a solution of excess l,l- 
diethoxyphthalan (5 equiv) and glacial acetic acid (0.2 
0 
2 R = TMS 
3 R=H 
0 0 
equiv) in toluene at reflux leads to in situ generation of 
4 5 R = CHa 
the highly reactive diene l-ethoxyisobenzofuran [19]. In 
6 R = Si(kPr), the presence of the quinone imine 2, Diels-Alder 
7 R=H cycloaddition takes place to form a 1:l mixture of the 
exo and endo adducts 8 (56 % combined yield). Both 
products are believed to result from diene addition to 
Fig. 4. Quinone imine precursors for dynemicin synthesis. 
Compounds 2-7, and similar structures, have previously been 
synthesized in enantiomerically pure form [l&3]. 
highly desirable, if not essential, feature given the high 
reactivity of this functional group. In addition, this 
convergent approach allows for the preparation of an 
enormous variety of dynemicin analogs by modification 
of the two coupling components. In the generalized 
scheme, the anthraquinone portion of dynemicin 
is introduced by the coupling of a substituted isobenzo- 
furan derivative with a quinone imine component that 
contains the (Z)-enediyne bridge and epoxide ring. We 
have previously synthesized several quinone imine pre- 
cursors of this type in enantiomerically pure form, to 
include the structures 2-7 (Fig. 4) [18].These quinone 
imines are stable materials, can be purified, stored, and 
the z-face of the quinone imine that is opposite the 
(Z)-enediyne bridge, with the indicated orientation (a 
potentially valuable control element for the introduction 
of dissymetrical anthraquinone coupling partners). 
Stirring the Diels-Alder adducts 8 with excess 
pyridinium chlorochromate (PCC) [20] (10 equiv) in 
dichloromethane at 23 “C leads to oxidative cleavage of 
the bicyclic ketal to form the anthraquinone 9; 
desilylation of the tertiary trimethylsilyl ether of 9 with 
triethylamine trihydrofluoride in acetonitrile then 
affords the purple dideoxydynemicin analog 10 in 30 % 
yield for the two steps after purification on silica gel. 
Hydrolysis of the dimethylketal group of 10 with 
p-toluenesulfonic acid in acetone at 23 “C produces the 
dynemicin analog 11 in 50 % yield. By using the 
Diels-Alder cycloaddition/oxidation methodology, the 
dideoxydynemicin analog 12 was prepared from the 
Et0 
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11 X =: OH 13 
12 X =: H 
Fig. 5. Preparation of dideoxydynemicin 
analogs by a Diels-Alder cycloaddition/ 
oxidation reaction sequence. Diels- 
Alder cycloaddition between the reactive 
diene 1 -ethoxyisobenzofuran (generated 
in situ from 1 ,l -diethoxyphthalan [191) 
and the quinone imine 2 (see Fig. 4) pro- 
duces adducts 8, which are transformed 
into the anthraquinone 9 with PCC 
(pyridinium chlorochromate [20]). 
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Fig. 6. Synthesis of dideoxydynemicin 
analogs from quinone imines by the 
phthalide addition method. The dideoxy- 
dynemicin analog 10 was synthesized in 
one step from the quinone imine 3; sim- 
ilarly, dideoxydynemicin A (compound 
14) was synthesized in one step from the 
quinone imine 6 (see Fig. 4). 
quinone imine 4 in 10 % yield for the two steps, and 
dideoxydynemicin methyl ester (13) was synthesized in 
6 % yield from the quinone imine 5.The latter products 
(12 and 13) were unstable to purification on silica gel, 
but could be purified by reverse-phase high-pressure 
liquid chromatography (HPLC). 
More recently, we have used a second protocol for the 
synthesis of anthraquinones that promises to proceed with 
substantially greater chemical efficiency (Fig. 6). Addition 
of 2.0 equivalents of lithiated cyanophthalide [21,22] to 
the quinone imine 3 at -78 “C in tetrahydrofuran and 
slow warming of the resultant solution to 23 “C produced 
the dideoxydynemicin analog 10 in 85 % yield after 
purification by chromatography on silica gel followed by 
Sephadex LH-20. Similarly, dideoxydynemicin A (14) was 
synthesized in a single step in 47 % yield by the addition 
of lithiated cyanophthalide to the quinone imine 6 at 
-78 “C, followed by warming to -30 “C and quenching 
with hydrogenfluoride pyridine complex. 
To synthesize the more highly oxidized anthraquinone 
ring of dynemicin A itself, it was necessary to modify the 
Diels-Alder cycloaddition/oxidation strategy (Fig. 7). 
15R=H 
LiN(TMS)z, 
TMSC, [s$s ;:&Jf$ 
SEMO 
SEMO TMSO 0 
Fig. 7. Modification of the Diels-Alder 
cycloaddition/oxidation synthetic strate- 
gy directed toward the preparation of 
the highly oxidized anthraquinone moi- 
ety of dynemicin A. 
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The oxygenated phthalides 15 and 16 served as 
precursors to the requisite isobenzofurans using a 
deprotonation-silylation sequence [23]. Treatment of 
phthalide 16 with lithium N,N-bis(trimethylsily1) 
amide in tetrahydrofuran at -78 “C and trapping of the 
resulting anion with trimethylsilyl chloride afforded 
the corresponding 0-trimethylsilyloxyisobenzofuran 
derivative, which, without isolation, formed the exo- 
oriented cycloadduct 18 in 34 % yield upon brief 
warming with quinone imine 2. Product 18 was a sen- 
sitive material, readily undergoing ring cleavage to 
form the phthalide 19 under even mildly basic condi- 
tions, a result that is reminiscent of transformations 
occurring within the tetracycline antibiotics [24,25]. 
Ring cleavage was avoided when the cycloadduct 18 
was treated with triethylamine trihydrofluoride in ace- 
tonitrile at 23 ‘C, thereby forming the red anthrol 
derivative 20 in 44 % yield. 
Although compound 20 lies only one oxidation state 
from the desired anthraquinone, a large series of oxi- 
dants failed to bring about this conversion. In reconsid- 
ering the problem, it was recognized that oxidation of 
the left-most ring of ‘18 from the hydroquinone to 
quinone level would produce an intermediate at the 
same level of oxidation as the desired anthraquinone, 
and one that is removed from that product only by the 
opening of the bicyclic ketal and tautomerization. With 
this in mind, the hydrolytically sensitive bis(trimethylsi- 
1yl)ether 17 was prepared from 15, in quantitative yield, 
by heating 15 with ?\5N-bis(trimethylsilyl)amine in 
tetrahydrofuran at reflux containing a trace of concen- 
trated sulfuric acid as catalyst (30 min), followed by the 
removal of volatiles in vacua [26]. Treatment of the 
residue with potassium AJJV-bis(trimethylsilyl)amide 
(1.04 equiv) in tetrahydrofuran and trapping of the 
resulting anion with trimethylsilyl chloride produced 
the tris(trimethylsilyloxy)isobenzofuran, as evidenced by 
the formation of the Diels-Alder adduct 21 (exo 
product) upon addition of quinone imine 2 and brief 
heating at 55 “C (Fig. 8). 
Direct addition of this highly sensitive product to an 
emerald green solution of cuprous chloride in pyridine 
under an oxygen atmosphere followed by the addition of 
hydrogen fluoride pyridine complex afforded the dyne- 
micin analog 22 directly, in 63 % yield for the two-step 
procedure. In the same way, the quinone imine 6 was 
transformed in two steps to dynemicin A (1) in 14 % 
yield. Synthetic dynemicin A was shown to be identical 
with an authentic sample of the natural product by spec- 
troscopic comparison, reverse-phase HPLC analysis (by 
co-injection), and circular dichroism. The latter estab- 
lishes for the first time the absolute configuration of 
natural dynemicin A as: 2S, 3S, 4S, 7R, 8R. 
DNA cleaving studies 
Preliminary evaluation of the DNA-cleaving activity of 
several of the synthetic dynemicin analogs described 
herein was undertaken by incubating each analog 
(50 FM) with a 3’-32P-labeled 193-base pair DNA 
restriction fragment, double-stranded calf thymus DNA 
(1.0 mM base pairs), and, in separate experiments, with 
each of the reducing cofactors NADPH and glutathione 
(20 n&I). The cleavage reactions were run for 12 h at 
37 “C and the cleavage products were analyzed by gel 
electrophoresis after precipitation and washing. As illus- 
trated in Fig. 9, DNA cleaving activity was observed with 
each analog tested (compounds 10-13); for comparison, 
lanes 3 and 8 show DNA cleavage by dynemicin A (1) 
under identical conditions using NADPH and 
glutathione, respectively, as activating factors. 
Analysis of the data shows that any variations in the 
sequence specificity of cleavage by the analogs examined 
thus far versus dynemicin A are modest at best. The eval- 
uation is made difficult because dynemicin A itself 
exhibits little sequence specificity of cleavage within this 
193-bp restriction fragment, raising questions as to 
whether the sequence specificity of DNA cleavage by 1 
is important in determining its antitumor activity. 
Greater variance is observed when the cleavage efficien- 
cies of natural and nonnatural dynemicins are compared. 
Fig. 8. Synthesis of the dynemicin analog 
22and dynemicin A by a modified Diels 
Alder cycloaddition/oxidation strategy 
employing the tris(trimethylsilyloxy)iso- 
benzofuran intermediate shown as the 
dienophile. Direct treatment of the 
Diels-Alder cycloadducts with hydrogen 
fluoride pyridine complex and cuprous 
chloride in pyridine under an atmos- 
phere of oxygen then produces the target 
anthraquinones. 
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Fig. 9. DNA cleavage of a 3’4abeled 193 base-pair restriction 
fragment of pBR322 (Eco RI/Ssp I digests) from the reaction of 
dynemicin A or synthetic anthraquinones 10, 11, 12, and 13 
with glutathione (GSH) or NADPH. Reactions were performed 
on a volume of 50 ul and contained calf thymus DNA (1 .O mM 
bp), 193 base-pair restriction fragment (-lo5 cpm), tris-HCI 
buffer (30 mM, pH 7.5), sodium chloride (50 mM), dynemicin A 
or synthetic anthraquinone (0.05 mM), and either glutathione 
(GSH, 20 mM) or NADPH (20 mM), as indicated. Reactions were 
incubated at 37 ‘C for 12 h. Lane C: 193 bp restriction fragment 
alone. Lane A: products from an adenine-specific cleavage reac- 
tion as described in [291. 
Fig. 10. Activation of the dideoxydynemicin analog 10 produces 
the expected Bergman cyclization product, compound 23. 
For example, whereas greater DNA cleavage is observed 
in the activation of 1 by NADPH than by glutathione 
(cleavage efficiencies: 5.7 and 4.0 %, respectively), the 
opposite is true with analog 10 (cleavage efficiencies: 3.5 
and 7.2 %, respectively, Fig. 9). Reactivity differences 
such as these may provide the basis for variations in bio- 
logical activity and, perhaps, therapeutic potential, and 
underscore the need for continued exploration of modi- 
fied dynemicin structures. The latter contention is 
further supported by the fact that several of these 
analogs, and compound 10 in particular, have exhibited 
potent anticancer activity in preliminary in vitro evalua- 
tions conducted by the National Cancer Institute against 
a panel of 60 human tumor cell lines and have been 
selected for further evaluation in vivo. 
In light of its biological activity and differential reactivity 
toward reducing cofactors versus dynemicin A (l), it was 
of interest to determine whether DNA cleavage by the 
analog 10 proceeded by a mechanism analogous to that 
of 1. Treatment of a methanolic solution of analog 10 
containing 1,4-cyclohexadiene with an aqueous solution 
of glutathione (20 equiv) led to clean formation of the 
Bergman cyclization product 23, isolated in 50 % yield 
after purification by reverse-phase HPLC (Fig. 10). 
Incubation of the analog 10 with NADPH or glu- 
tathione in water in the presence of double-stranded calf 
thymus DNA produced the same product, 23, in -45 % 
yield in each case.Thus, it would appear that in terms of 
net transformation, compound 10 behaves as a perfect 
analog of 1, although the details of these processes 
remain to be established. 
Significance 
Dynemicin A is a potent natural antitumor antibi- 
otic and an important new chemotherapeutic lead. 
Because of its structural complexity and high reac- 
tivity, it has not been possible to substantially 
modify the natural product so as to produce 
analogs for study. Prior to this work, the absolute 
configuration of dynemicin A was unknown. 
We have developed an unambiguous, enantiose- 
lective laboratory synthetic route to dynemicin A. 
By comparing enantiomerically pure, synthetic 
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dynemicin A with material derived from fermen- 
tation, the absolute configuration of the natural 
product was established. A key feature of the syn- 
thetic pathway we have developed is the fact that 
a wide variety of structural analogs of dynemicin 
A, compounds which could not have been pre- 
pared from the natural product, are now available 
for study, as demonstrated by the preparation of 
several active dynemicin analogs. These 
compounds have shown promising activity in 
DNA cleaving assays and in vitro screening against 
human tumor cell lines. It is anticipated that the 
availability of these and like molecules will lead to 
a greater understanding of the chemistry of 
dynemicin A and a more extensive exploration of 
its chemotherapeutic potential. 
Materials and methods 
Synthesis of dideoxydynemicin anthraquinones by the 
Die/s-Alder addition/PC% oxidation method. Preparation 
of dideoxydynemicin analog 70 
A 50-ml modified Schlenk flask equipped with a reflux con- 
denser was charged with quinone imine 2 (160 mg, 0.35 
mmol, 1 equiv), 1,1-diethoxyphthalan (370 mg, 1.78 mmol, 
5 equiv), acetic acid (5 l.tl, 0.09 mmol, 0.2 equiv), and toluene 
(5 ml).The resulting solution was deoxygenated, then heated at 
reflux for 30 min. The reaction mixture was cooled to 23 “C, 
then was partitioned between saturated aqueous sodium bicar- 
bonate solution (100 ml) and dichloromethane (100 ml). The 
organic layer was dried over sodium sulfate and was concen- 
trated.The residue was purified by flash column chromatogra- 
phy (20 % ethyl acetate-hexanes) to afford the Diels-Alder 
adduct as a colorless oil (122 mg, 56 %, 1:l mixture of 
exo:endo isomers). A solution of the latter product (115 mg, 
0.19 mmol, 1 equiv) in dichloromethane (30 ml) at 23 “C was 
treated with solid pyridinium chlorochromate (390 mg, 
1.90 mmol, 10 equiv) and the resulting purple solution was 
stirred at 23 “C for 10 min. The reaction mixture was parti- 
tioned between saturated aqueous sodium bicarbonate solution 
(500 ml) and dichloromethane (200 ml).The organic layer was 
treated with triethylamine (1 ml), then dried over sodium 
sulfate and concentrated to a volume of -10 ml.The product 
was purified by flash column chromatography (20 % ethyl 
acetate-hexanes) to afford a dark purple film which was dis- 
solved in acetonitrile (5 ml).The resulting purple solution was 
treated with triethylamine trihydrofluoride (610 l.tL3.8 mmol, 
20 equiv), then stirred at 23 “C for 3 h.The reaction mixture 
was partitioned between saturated aqueous sodium bicarbonate 
solution (50 ml) and dichloromethane (50 ml). The organic 
layer was dried over sodium sulfate and concentrated. The 
residue was purified by flash column chromatography (20 % 
ethyl acetate-hexanes) to afford dynemicin analog 10 as a dark 
purple film (30 mg, 36 %). 
Synthesis of dideoxydynemicin anthraquinones by the 
phthalide addition method. Preparation of dideoxydyne- 
micin analog 10 
A solution of t-butyllithium in pentane (1.7 M, 0.13 ml, 
0.21 mmol, 2.5 equiv) was added to a solution of cyanoph- 
thalide (27 mg, 0.099 mmol, 2.0 equiv) in tetrahydrofuran (1.0 
ml) at -78 “C.The resulting bright orange solution was stirred 
for 10 min at -78 “C whereupon a solution of quinone imine 
3 (32 mg, 0.09 mmol, 1.0 equiv) in tetrahydrofuran (1.0 ml) 
was added, the cooling bath was removed, and the reaction 
mixture was allowed to warm to 23 “C. After 10 min, the 
purple reaction mixture was applied directly to a flash 
chromatography column loaded with ethyl acetate-hexanes 
(1:l) and the product anthraquinone was eluted using the 
same solvent mixture. Concentration of the appropriate 
column fractions and further purification of the residue by 
chromatography on Sephadex LH-20 (methanol) afforded the 
anthraquinone 10 as a dark purple oil (36 mg, 85 %). 
Dideoxydynemicin analog 10 
‘H NMR (500 MHz, C,D,): 6 13.76 (s, IH, aryl OH), 10.54 
(d, IHJ = 4.1 Hz, NH), 9.17 (s, IH, m-aryl H), 8.30 (d, lH,j 
= 7.9 Hz, o-C(O)-aryl H), 8.10 (d, lH,j = 7.2 Hz, o-C(O)- 
aryl H), 7.10 (td, IH,] = 7.9, 1.2 Hz, m-C(O)-aryl H), 7.01 
(td, lH, _I = 6.9, 1.2 Hz, m-C(O)-aryl H), 5.11 (s, 2H, 
HC=CH), 3.84 (d, lH,j = 4.3 Hz, NCH), 3.33 (s, 3H, 
OCH,), 2.93 (s, 3H, OCH,), 2.20 (m, IH, CHCH,), 2.12 (t, 
lH,J = 13.9 Hz, CHCH,), 1.78 (dd, lH,j = 11.9, 4.7 Hz, 
CHCH,), 0.92 (d, 3H,j = 7.3 Hz, CHCH,). Fourier-trans- 
form infra red spectroscopy (FTIR) (neat, cm-‘): 2944 (m), 
2851 (w), 1621(m), 1590 (s), 1569 (m), 1492 (s), 1462 (m), 
1251 (s), 1154 (m), and 1051 (s). HRMS (FAB): m/z calcd for 
C&H,,NO, (MH)+ 510.1553,found 510.1552. 
Synthesis of dynemicin anthraquinones by the Diels- 
Alder addition/oxidation method. Preparation of 
dynemicin analog 22 
A solution of potassium N,N-bis(trimethylsilyl)amide in 
toluene (0.5 M, 1.73 ml, 0.867 mmol, 26 equiv) was added to a 
solution of 4,7-bis(trimethylsilyloxy)phthalide (17, 259 mg, 
0.834 mmol, 25 equiv) in tetrahydrofuran (5.0 ml) at -78 ‘C, 
and the resulting bright yellow solution was stirred for 25 min 
at -78 “C. During this time the reaction mixture darkened to 
yellow-brown. A I:2 mixture of chlorotrimethylsilane and tri- 
ethylamine (415 ~1, 1.00 mmol in chlorotrimethylsilane, 30 
equiv) was added.The reaction mixture was brought to -20 “C 
where the reaction solution became pale yellow within 5 min. 
At this point, a solution of the quinone imine 2 (15.0 mg, 
33.4 ymol, 1 equiv) in tetrahydrofuran (1.5 ml) was transferred 
to the cold reaction mixture.The reaction flask was placed in an 
oil bath preheated to 55 “C and the reaction mixture was held 
at that temperature for 15 min.The flask was then allowed to 
cool to 23 “C and the reaction solution was concentrated to 
afford a light yellow residue. This residue was dissolved in pyri- 
dine (1 ml) and the resulting solution was transferred to an 
emerald green solution of copper(I) chloride (13.0 mg, 
0.133 mmol, 4.0 equiv) in pyridine (1.0 ml) under an atmos- 
phere of oxygen, producing an olive-green solution. To this 
solution was added a 600+1 aliquot of an ice-cold solution 
composed of hydrogen fluoride pyridine complex (1.0 ml), 
pyridine (4.0 ml), and tetrahydrofuran (10 ml). Oxygen was 
bubbled gently through the reaction mixture, which quickly 
turned black. After 10 min, the flow of oxygen gas was discon- 
tinued and the product solution was partitioned between ethyl 
acetate (50 ml) and water (50 ml). The aqueous layer was 
further extracted with ethyl acetate (50 ml) and the combined 
organic layers were washed sequentially with a saturated 
aqueous solution of EDTA (50 ml) and brine (3 x 50 ml).The 
aqueous layers were combined and extracted with ethyl acetate 
(50 ml). The combined ethyl acetate extracts were dried with 
sodium sulfate and were concentrated, and the residue was 
purified by chromatography on Sephadex LH-20 (methanol) to 
afford dynemicin analog 22 as a dark blue film (13.0 mg, 63 %). 
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Dynemicin analog 22 
‘H NMR (500 MHZ, C6D6): 6 13.58 (s, lH, aryl OH), 12.84 
(s, lH, aryl OH), 12.45 (s, lH, aryl OH), 9.96 (d, lH,j = 3.9 
Hz, NH), 9.01 (s, lH, m-aryl H), 6.96 (d, lH,] = 9.3 Hz, 
o-aryl H), 6.86 (d, lH,j = 9.2 Hz, o-aryl H), 5.22 (d, lH, J = 
9.9 Hz, C=C-CH=C), 5.18 (d, lH, / = 10.0 Hz, 
C=C-CH=C), 3.88 (d, lH,j = 3.2 Hz, NCH), 3.47 (s, 3H, 
OCH,), 3.06 (s, 3H, OCH,), 2.27 (m, lH, CH,CH), 2.19 (t, 
lH,] = 13.7 Hz, CHCH,), 1.89 (dd, lH,] = 13.8, 4.5 Hz, 
CHCH,), 0.98 (d, 3H,_I = 7.2 Hz, CHCH,), 0.45 (s, 9H, 
OSi(CH,),). FTIR (neat, cm-‘): 3600-3300 (br, m), 2959 (m), 
2939 (m), 2851 (m), 1746 (w), 1579 (s), 1490 (w), 1450 (s), 
1303 (s), 1249 (w), 1175 (s), 1057 (m). HRMS (FAB): m/z 
calcd for t&H,,NO,Si (M)+ 613.1768, found 613.1779. 
Synthesis of dideoxydynemicin analog 11 
Hydrolysis of dideoxydynemicin analog 10 (4 mg, 0.007 
mmol, 1 equiv) in acetone (5 ml) containing p-toluenesulfonic 
acid (50 mg, 0.26 mmol, 40 equiv) at 23 “C for 2 h followed by 
aqueous work-up and purification by flash column chromat- 
ography (20 % ethyl acetate-hexanes) afforded the dideoxy- 
dynemicin analog 11 as a dark purple oil (2.0 mg, 50 %). 
Dideoxydynemicin analog 11 
‘H NMR (500 MHZ, C,D,), 6: 13.59 (s, lH, aryl OH), 10.31 
(d, lH,j= 4.2 Hz,NH),9.06 (s, lH, m-aryl H), 8.29 (d, lH,]= 
7.0 HZ, o-C(O)-aryl I-I), 8.07 (d, lH,J = 7.9 Hz, o-C(O)-aryl 
H), 7.10 (td, lH,j= 7.3,1.3 Hz, m-C(O)-aryl H),7.02 (td, lH, 
J= 7.3,1.1 Hz, m-C(O)-aryi H), 5.14 (dd, lH,j= 10.6,1.3 Hz, 
NCH-C-C-CH), 5.09 (d, lH,] = 10.1 Hz, CEC-CH), 4.86 (s, 
lH, OH), 3.66 (dd, lH,+/ = 3.9, 1.2 Hz, NCH), 2.55 (dd, ZH,] 
= 9.4,8.4 Hz, CHCH,),2.24 (m, lH, CHCH,),2.18 (dd, lH,] 
= 9.4, 7.4 Hz, CHCH,), 0.80 (d, 3H,j = 7.1 Hz, CHCH,). 
FTIR (neat, cm-‘): 3423 (w), 2922 (s), 2849 (w), 1742 (m), 1622 
(m), 1585 (s), 1486 (m), 1351 (m), 1272 (s). HRMS (FAB): m/z 
calcd for C,,H,,NO, (MH)+ 464.1134, found 464.1152. 
Synthesis of dideoxydynemicin analog 12 
Dideoxydynemicin analog 12 was prepared in 10 % yield (4.0- 
mg scale) following the Diels-Alder addition/PCC oxidation 
method described above for analog 10. 
Dideoxydynemicin analog 12 
‘H NMR (500 MHz, C,D,), 6: 13.57 (s, lH, aryl OH), 10.24 
(d, lH,j = 4.2 HZ, NH), 8.26 (d, lH,j = 7.0 Hz, o-C(O)-aryi 
H), 8.10 (d, lH,] = 7.6 Hz, o-C(O)-aryl H), 7.20 (s, lH, m- 
aryl H), 7.10 (td, lH,J = 7.3, 1.3 Hz, m-C(O)-aryl H), 7.02 
(td, lH,j = 7.3, 1.1 Hz, m-C(O)-aryl H), 5.14 (dd, lH,_I = 
9.8, 1.1 Hz, C=C-CH=C), 5.11 (dd, lH,] = 10.1, 1.4 Hz, 
C=C-CH=C), 3.92 (s, lH, C=C-CH), 3.58 (d, lH,j = 3.9 
HZ, NCH), 2.48 (dd, lH,j = 15.9,7.7 Hz, CHCH,), 2.28 (m, 
lH, CHCH,), 2.21 (dd, lH,j = 15.8,4.4 Hz, CHCH,), 1.00 
(d, 3H,j = 7.4 HZ, CHCH,). FTIR (neat, cm-l): 2923 (w), 
2848 (w), 1710 (m), 1620 (s), 1588 (s), 1483 (m), 1356 (m), 
1257 (s). HRMS (FAB): m/z &cd for C,,H,,NO, (MH)+ 
448.1185,found 448.1155. 
Synthesis of dideoxydynemicin A methyl ester (13) 
Dideoxydynemicin A methyl ester (13) was prepared in 6 % 
yield (17.0-mg scale) following the Diels-Alder addition/PCC 
oxidation method described above for analog 10. 
Dideoxydynemicin A methyl ester (13) 
‘H NMR (500 MHZ, C,D,), d: 13.71 (s, lH, aryl OH), 10.29 
(d, lH,j= 4.2 HZ, NH), 8.30 (d, lH,]= 7.0 Hz, o-C(O)-aryl 
H), 8.12 (d, lH,j = 7.6 Hz, o-C(O)-aryl H), 7.43 (s, lH, m- 
aryl H), 7.20 (td, lH,_I = 7.3, 1.3 Hz, m-C(O)-aryl H), 7.10 
(td, lH,j= 7.3,1.1 Hz, m-C(O)-aryl H),5.17 (dd, lH,J= 9.8, 
1.1 Hz, C=C-CH=C), 5.13 (dd, lH, J = 10.0, 1.2 Hz, 
C=C-CH=C), 3.90 (s, lH, C=C-CH), 3.76 (q, lH,_I = 7.2 
Hz, CHCH,), 3.58 (d, lH,] = 4.0 Hz, NCH), 3.45 (s, 6H, 
CO&H,, OCH,), 1.45 (d, 3H,j = 7.3 Hz, CHCH,). FTIR 
(neat, cm-‘): 2922 (m), 2850 (w), 1711 (m), 1693 (m), 1588 (s), 
1484 (m), 1357 (m), 1257 (s). HRMS (FAB): m/z calcd for 
C,,H,,NO, (MH)+ 520.1396, found 520.1434. 
Synthesis of dideoxydynemicin A (14) 
Dideoxydynemicin A was prepared following the phthalide 
addition method described above for dynemicin analog 10, 
albeit employing the quinone imine 6 (8.0 mg, 0.015 mmol) 
as substrate.The reaction also differed in that hydrogen fluo- 
ride pyridine complex (75 ~1) was used to quench the reac- 
tion (at -30 “C) in order to effect cleavage of the 
triisopropylsilyl ester. Dideoxydynemicin A was obtained as a 
dark purple oil (3.6 mg, 47 %) after purification on 
Sephadex LH-20 gel (methanol). 
Dideoxydynemicin A (14) 
‘H NMR (500 MHz, C6D6): 6 13.81 (s, lH, aryl OH), 10.26 
(d, lH,j = 3.7 Hz, NH), 8.34 (d, lH,j = 6.9 Hz, o-C(O)-aryl 
H), 8.15 (d, lH,] = 7.2 Hz, o-C(O)-aryl H), 7.42 (s, lH, m- 
aryl H), 7.25 (td, lH,j = 6.9, 1.4 Hz, m-C(O)-aryl H), 7.05 
(td, lH,J = 7.2, 1.3 Hz, m-C(O)-aryl H), 5.23 (d, lH,] = 9.9 
Hz, C=C-CH=C), 5.15 (d, lH,J = 9.8 Hz, C=C-CH=C), 
3.95 (q, lH,j = 7.3 Hz, CHCH,), 3.72 (br s, lH, C=C-CH), 
3.51 (d, lH,j = 3.7 Hz, NCH), 2.75 (s, 3H, OCH,), 1.49 (d, 
3H,j = 7.3 HZ, CHCH,). FTIR (neat, cn-I): 3350 (br), 2964 
(s), 2929 (m), 2848 (w), 1702 (s), 1621 (s), 1586 (m), 1388 (m), 
1240 (m), 1120 (s), 1000 (s). MS (FAB): W/Z calcd for 
CXOHV, NO, (M)’ 505.1, found 505.1. 
Synthesis of dynemicin A (1) 
Dynemicin A was prepared following the procedure described 
above for dynemicin analog 22, but employing the quinone 
imine 6 as substrate. In addition, the amount of isobenzofuran 
precursor was reduced from 25 to 7 equiv, heating at 55 “C was 
reduced from 15 to 5 min, and purification was achieved by 
chromatography on Sephadex LH-20 gel eluting with 20 % 
acetonitrile-methanol. In this manner, a 9.0-mg portion of the 
quinone imine 6 was transformed into 1.3 mg of pure dyne- 
micin A (14 % yield). Synthetic dynemicin A was shown to be 
identical to an authentic sample by spectroscopic comparison 
(‘H NMR, infra-red, circular dichroism) and by chromato- 
graphic behavior (reverse-phase HPLC, co-injection). 
Dynemicin A (1) 
‘H NMR (400 MHz, C6D6): 6 13.45 (br s, lH, aryl OH), 
12.91 (br S, lH, aryl OH), 12.43 (br s, lH, aryl OH), 9.77 (d, 
lH,j = 4.8 HZ, NH), 7.35 (s, lH, m-aryl H), 6.95 (d, lH,] = 
9.2 HZ, o-aryl H), 6.85 (d, lH,j = 9.2 Hz, o-aryl H), 5.22 (dd, 
lH,j = 10.0, 1.5 Hz, C=C-CH=C), 5.14 (dd, lH,J = 10.0, 
1.5 Hz, C=C-CH=C), 3.94 (q, lH,] = 7.3 Hz, CH,CH), 3.70 
(d, lH,J = 1.5 Hz, C=C-CH), 3.53 (dd, lH,] = 4.8, 1.5 Hz, 
NCH), 2.87 (s, 3H, OCH,), 1.47 (d, 3H, / = 7.3 Hz, 
CHCH,). ‘H NMR (400 MHz, DMSO): 6 13.13 (s, lH, aryl 
OH), 12.73 (s, lH, aryl OH), 12.14 (s, lH, aryl OH), 9.85 (br 
S, lH, NH), 8.04 (s, lH, m-aryl H), 7.37 (br m, 2H, o-aryl H), 
6.09 (br d, lH,j= 10.0 Hz, C=C-CH=C), 6.05 (br d, lH,] = 
10.0 HZ, C=C-CH=C), 5.07 (br m, lH, NCH), 4.89 (br s, 
lH, C=C-CH), 3.81 (s, 3H, OCH,), 3.57 (m, lH, CH,CH), 
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1.26 (d, 3H,J = 7.0 Hz, CHCH,). FTIR (neat, cm-‘): 3686- 
2730 (br, m), 3405 (br, m), 3285 (m), 2924 (w), 2854 (w), 
1750-1500 (br, m), 1642 (m), 1585 (vs), 1471 (s), 1395 (s), 1295 
(sh), 1274 (s), 1189 (s), 1169 (s), 1144 (m), 1099 (w), 1034 (m), 
969 (w), 923 (w), 783 (w). MS(FAB): m/z calcd for 
C,,H,,NO, (MH)+ 538.1, found 538.1. 
Preparation of 3’-32P-labeled 7 93-base pair restriction 
fragment 
Plasmid pBR322 (40 plO.25 l.tg ml-‘, Boehringer Mannheim) 
was precipitated by the addition of aqueous ammonium 
acetate buffer solution (20 ~1, 8 M, pH 7) and ethanol (180 
IQ, followed by centrifugation at 2 “C (16 000 g, 30 min), then 
washed with aqueous ethanol (100 @,70 %).The DNA pellet 
was dried on a Savant rotary speed vat, then was dissolved in 
water (90 1.11). Digestion buffer H (10 ~1, Boehringer 
Mannheim) was added, and the plasmid was digested with Eco 
RI (4 @, 40 units, Boehringer Mannheim) and Ssp I (4 ~1, 
40 units, Boehringer Mannheim) at 37 “C for 6 h.The diges- 
tion was quenched by extracting the reaction solution twice 
with phenol:chloroform (100 ~1, 1:l v/v), and the DNA was 
precipitated from the aqueous layer by the addition of aqueous 
ammonium acetate buffer solution (50 1.11, 8 M, pH 7) and 
ethanol (400 @), followed by centrifugation at 2 “C (16 000 g, 
30 min). The DNA pellet was washed with aqueous ethanol 
(100 ~1, 70 %), then dried. The DNA was dissolved in water 
(18 @), then mixed with aqueous dithiothreitol solution (4 ~1, 
100 mM), Sequenase 2.0 buffer (8 1.11, USB), and [&32P]- 
dATP (10 &200 /.tCi, N:EN, 26000 Ci mmol-‘). The restric- 
tion fragment was 3’-labeled with SequenaseVersion 2.0 (2 /,tl, 
25 units, USB) at 23 “C for 3 h, then treated with aqueous 
dATP solution (5 ~1, 10 n-&l) and SequenaseVersion 2.0 (2 ~1, 
25 units, USB) and incubated further at 23 “C for 2 h. The 
reaction solution was eluted through a NICK column 
(Pharmacia) to remove unincorporated 32P-dATP, and the 
eluant containing the labeled fragment was concentrated to a 
volume of 100 ~.tl. The labeled fragment was precipitated by 
the addition of aqueous ammonium acetate buffer solution 
(50 @,8 M, pH 7) and ethanol (400 pl), followed by centrifu- 
gation at 2 “C (16 000 g, 30 min), then was washed with 
aqueous ethanol (100 l.tl, 70 %) and dried. The 193-base pair 
fragment was dissolved in water (20 ~1) and Ficoll loading 
buffer (5 /.tl), then purified over a non-denaturing polyacry- 
lamide gel (8 %, 0.8 mm thickness) [27].The band containing 
the 193-base pair fragment was located by autoradiography 
and was excised from the gel.The gel slice was crushed thor- 
oughly and, after combination with aqueous Nonidet P-40 
detergent solution (700 11, 0.05 %, Sigma), was vortexed for 
6 h at 23 “C.The resulting suspension was filtered through a 
Centrex filter (0.45 /.tm) and the filtrate was extracted twice 
with phenol:chloroform (400 /.tl, 1:l v/v), then concentrated 
to a volume of 100 yl.The labeled product was precipitated by 
the addition of aqueous ammonium acetate buffer solution 
(50 ~1, 8 M, pH 7) and ethanol (400 pl), followed by centrifu- 
gation at 2 “C (16 000 x g, 30 min), then washed with aqueous 
ethanol (100 ~1, 70 %). The purified labeled fragment was 
stored frozen in tris-HCl aqueous buffer solution (10 mM, 
pH 7.4) containing EDTA (1 mM). 
Analysis of DNA cleavage products, general 
The products from a given DNA cleavage reaction were pre- 
cipitated by the addition of aqueous ammonium acetate buffer 
solution (50 ~1, 8 M, pH 7) and ethanol (250 pl), followed by 
centrifugation at 2 “C (16 000 g, 20 mm). The resulting 
product pellet was washed with aqueous ethanol (100 ~1, 
70 %), dried, then dissolved in formamide loading buffer (10 
/.tl), and the resulting solution transferred to a 0.65-ml 
Eppendorf tube. After assaying for radioactivity with a 
Beckman LS 6000SC scintillation counter, the solution was 
diluted with additional formamide loading buffer so as to 
produce a radiation density of 3000 cpm /.t-‘. After heating at 
80 “C for 3 min to induce denaturation, the solution (5 ~1) was 
analyzed by gel electrophoresis. Cleavage products were loaded 
onto a denaturing polyacrylamide gel (8 %, 42 x 34 cm, 0.4 
mm thickness) and were separated by electrophoresis in 1 x 
TBE buffer at 2000V for 15 min and then at 15OOV until the 
bromophenol blue dye had migrated off the gel [27]. The gel 
was exposed to a storage phosphor plate and the DNA cleav- 
age products were quantified with a Molecular Dynamics 
400-S PhosphorImager. 
Analysis of DNA cleavage by dynemicin A and synthetic 
analogs 10, 11, 12, and 13 
Reactions were performed at 37 “C in 1.5-ml Eppendorf 
tubes containing a total reaction volume of 50 ~1. A 5-~1 
aliquot of a solution of dynemicin A (0.5 mM) in DMSO was 
combined with a solution of double-stranded calf thymus 
DNA (5 ~1, 10 mM bp) in water, tris-HCl aqueous buffer 
solution (15 ~1, 100 mM, pH 7.5), aqueous sodium chloride 
solution (5 ~1, 500 mM), water (15 j.tl), and 3’-32P-labeled 
restriction fragment (-100 000 cpm). The reaction was initi- 
ated at 23 “C by the addition of an aqueous solution of glu- 
tathione (5 /.tl, 200 mM, pH 7.5) to the remaining solution, 
thus producing the following concentrations of solution com- 
ponents at the onset of the reaction: dynemicin A, 0.05 mM; 
GSH, 20 mM; double-stranded calf thymus DNA, 1 .O mM bp; 
tris-HCl buffer, 30 mM; sodium chloride, 50 mM.The reac- 
tion solution was incubated at 37 “C for 12 h and the cleavage 
products were precipitated and analyzed as described above. 
DNA cleavage reactions employing the synthetic dynemicin 
analogues 10, 11, 12, and 13 were conducted in an identical 
manner, employing a solution of each respective dynemicin 
analog in DMSO (0.5 mM) in lieu of dynemicin A. DNA 
cleavage reactions employing NADPH were conducted in an 
identical manner, employing an aqueous solution of NADPH 
(200 mM) in lieu of GSH. 
Reaction of 10 with GSH and NADPH in the presence of 
DNA; HPLC analysis 
The reaction of 10 with GSH was performed at 37 “C in a 
1.5-ml Eppendorf tube containing a total reaction volume of 
100 ~1, as follows. A IO-p1 aliquot of a solution of 10 (1.0 
mM) in methanol containing 2,5-dimethoxybenzyl alcohol 
(1.0 mM, internal HPLC standard) was combined with a 
solution of double-stranded calf thymus DNA (10 ~1, 
10 mM bp) in water, tris-HCl aqueous buffer solution 
(30 ~1, 100 mM, pH 7.5), aqueous sodium chloride solution 
(10 ~1, 500 mM), aqueous 1,2-bis(hydroxymethyl)-1,4- 
cyclohexadiene [28] (10 ~.tl, 500 mM, a hydrogen atom 
source), and water (10 ~1). The reaction was initiated at 
37 “C by the addition of an aqueous solution of GSH (20 /.tl, 
100 mM, pH 7.5), thus producing the following concentra- 
tions of solution components at the onset of the reaction: 
IO, 0.1 mM; GSH, 20 mM; double-stranded calf thymus 
DNA, 1.0 mM bp; tris-HCl buffer, 30 mM; sodium 
chloride, 50 mM; 1,2-bis(hydroxymethyl)-1 ,/t-cyclohexadi- 
ene, 50 mM. The reaction solution was incubated at 37 “C 
for 16 h. HPLC analysis of the reaction product (40-~.tl injec- 
tion volume) employed a Beckman HPLC system equipped 
with a Beckman Ultrasphere ODS (C,,, 5 Frn) rp-HPLC 
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column, 4.6 x 250 mm, flow = 0.40 ml min-’ with a linear 
gradient of acetonitrile:aqueous ammonium acetate buffer 
solution (10 mM, pH 6.0): lo:90 v/v acetonitrile: aqueous 
ammonium acetate buffer to 100 % acetonitrile over 
a period of 50 min. Peaks were detected by ultraviolet 
absorption at 255 nm with a Beckman 168 Programmable 
Photodiode Detector. An initial ratio of 10 to 
2,5-dimethoxybenzyl alcohol was established by HPLC 
analysis of the methanolic solution of 10. Product 23 
(retention time tR - 44 min) was formed in -45 % yield, as 
determined by integration against the internal standard. The 
identity of product 23 was established by co-injection with 
an authentic sample of 23 (see below). The reaction with 
NADPH was conducted in an identical manner, employing 
an aqueous solution of NADPH (200 mM) in lieu of GSH 
and formed product 23 in -45 % yield, as determined by 
integration against the internal standard. 
Preparation of product 23 
A solution of dynemicin analog 10 (6 mg, 0.012 mmol, 1 
equiv) in methanol (9 ml) containing 2,5-dimethoxybenzyl 
alcohol (1 mM, internal HPLC standard) was treated sequen- 
tially with 1,4-cyclohexadiene (1 .O ml, 10 mmol, 830 equiv), 
aqueous glutathione solution (200 mM, 1.0 ml, 0.20 mmol, 
20 equiv), and triethylamine (0.30 ml, 220 mg, 2.2 mmol, 
180 equiv), thus producing the following concentrations of 
solution components at the onset of the reaction: 10, 1 mM; 
1,4-cyclohexadiene, 1 M; glutathione, 20 mM; triethylamine, 
200 mM. The solution was incubated at 37 “C for 12 h, 
during which time its color changed from violet to dark 
purple.The product solution was concentrated to a volume of 
-0.5 ml, then was diluted with water (1 ml). Purification 
of the product was achieved by reverse-phase HPLC, using 
three separate 500~~1 injection volumes, on a Beckman 
Ultrasphere ODS (C,,, 5 Frn) rp-HPLC column, 10 x 
250 mm, as part of a Beckman HPLC system, flow = 2.00 ml 
min-’ , with a linear gradient of acetonitrile:aqueous 
ammonium acetate buffer solution (10 mM, pH 6.0): lo:90 
v/v acetonitrile:aqueous ammonium acetate buffer to 9O:lO 
v/v acetonitrile:aqueous ammonium acetate buffer over a 
period of 50 min. Peaks were detected by ultraviolet absorp- 
tion at 250 nm with a Beckman 168 Programmable 
Photodiode Detector. Fractions containing product 23 
(retention time tR -45 min) were collected and pooled. 
Acetonitrile was removed by rotary evaporation and the 
resulting concentrated aqueous solution was lyophilized. 
Product 23 was obtained as a dark purple film (3 mg, 50 %, as 
determined by integration against the internal standard). 
Product 23 
‘H NMR (500 MHz, C,D,),: 6 13.80 (s, lH, aryl OH), 10.48 
(d, lH,j = 4.3 Hz, NH), 8.27 (dd, lH,] = 8.0, 1.0 Hz, o- 
C(O)-aryl H), 8.15 (dd, lH,J = 7.8, 1.2 Hz, o-C(O)-aryl H), 
7.41 (dd, lH,]= 8.0, 1.1 Hz,aromatized core),7.25 (s, lH, m- 
aryl H), 7.12 (td, lH,j = 7.8, 1.3 Hz, m-C(O)-aryl H), 7.04 
(td, lH,j = 8.5,1.3 Hz, m-C(O)-aryl H), 6.96 (td, 1HJ = 7.4, 
1.2 Hz, aromatized core), 6.92 (td, lH,] = 7.3, 1.7 Hz, aroma- 
tized core), 6.85 (dd, lH,J = 7.0, 1.3 Hz, aromatized core), 
3.91 (dd, 1HJ = 4.4, 1.9 Hz, NCH), 3.50 (d, lH,j = 1.7 Hz, 
C(OH)-CH-C(OH)), 3.11 (s, 3H, OCH,), 3.00 (s, 3H, 
OCH,), 2.93 (s, lH, OH), 2.66 (s, lH, OH), 2.43 (m, lH, 
CHCH,), 1.58 (dd, lH,j = 14.5, 5.9 Hz, CHCH,), 0.96 (d, 
3HJ = 6.8 Hz, CHCH,), 0.55 (t, lH,j = 13.9 Hz, CHCH,). 
FTIR (neat, cm-*): 3446 (m, br), 2954 (m), 2923 (s), 2851 (w), 
1615 (m), 1585 (s), 1492 (m), 1354 (s), 1251 (s), 1051 (s). 
HRMS (FAB): m/z calcd for C3,,HZ8N0, [MH]+ 514.1866, 
found 514.1869. 
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